Belgian spin-off targets medical unmet needs
Our expert's opinion
"Belgian spin-offs keep finding ways to target medical unmet need. This time Lundbeck takes a chance on the Belgian Biotech sector aiming to make breakthroughs in its preclinical portfolio for schizophrenia, depression, Alzheimer’s and Parkinson’s disease through a collaboration with Confo Therapeutics."
- Jorge Alfonso, Associate Consultant
Lundbeck in licensing deal with Confo Therapeutics
Danish CNS specialist Lundbeck is to pay an initial five million euros ($5.9 million) to use the technology of Belgian drug discovery company Confo Therapeutics to discover small molecule compounds acting upon two G-protein coupled receptors.
There will also be further milestone payments, as well as tiered royalties on the annual net sales of any products resulting from the collaboration, which gives Lundbeck an option to an exclusive license to develop, manufacture and commercialize such compounds.
Working on GPCRs that Lundbeck has not been able to address previously will allow the company to initiate new projects in its preclinical portfolio for schizophrenia, depression, Alzheimer’s and Parkinson’s disease.
Source: the pharma letter